Circulating CD34+ progenitor cell frequency is associated with clinical and genetic factors

Blood

Volumn 121, Issue 8, 2013, Pages

  Cohen, Kenneth S ^a,b   Cheng, Susan ^a,c   Larson, Martin G ^c,d   Cupples, L Adrienne ^e   McCabe, Elizabeth L ^a   Wang, Ying A ^e   Ngwa, Julius S ^e   Martin, Roderick P ^a,f   Klein, Rachael J ^a   Hashmi, Basma ^g   Ge, Yin ^a   O'Donnell, Christopher J ^a,c,h   Vasan, Ramachandran S ^c,i   Shaw, Stanley Y ^a,j   Wang, Thomas J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d Boston University   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f GENZYME CORPORATION   (United States)

^g HARVARD UNIVERSITY   (United States)

^h NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Simches Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CD34 SELECTION; CELL POPULATION; CHROMOSOME 1; CHROMOSOME 11; COHORT ANALYSIS; ENVIRONMENTAL FACTOR; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HEMATOPOIETIC STEM CELL; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

EID: 84874428676     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-424846     Document Type: Article

References (47)

1. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007;2(4):805-810. (Pubitemid 46745577)
2. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10(1 Pt 1):228-233. (Pubitemid 38114184)
3. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevaci-zumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145-147. (Pubitemid 38524883)
4. Lev EI, Leshem-Lev D, Mager A, et al. Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. Eur Heart J. 2010;31(21):2625-2632.
5. Beijk MA, Klomp M, Verouden NJ, et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J. 2010;31(9):1055-1064.
6. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angio-genesis. Science. 1997;275(5302):964-967. (Pubitemid 27087709)
7. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952-958. (Pubitemid 30062717)
8. Losordo DW, Henry TD, Davidson C, et al. In-tramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428-436.
9. Gupta R, Losordo DW. Cell therapy for critical limb ischemia: moving forward one step at atime. Circ Cardiovasc Interv. 2011;4(1):2-5.
10. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol. 2007;49(7):741-752.
11. Zavada J, Kideryova L, Pytlik R, Hruskova Z, Tesar V. Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vas-culitis. Rheumatology (Oxford). 2009;48(10):1197-1201.
12. Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol. 2009;5(6):332-340.
13. Fadini GP, Avogaro A, Ferraccioli G, Agostini C. Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J. 2010;35(2):418-425.
14. Fadini GP, Schiavon M, Cantini M, et al. Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells. 2006;24(7):1806-1813. (Pubitemid 44474194)
15. Taylor M, Rossler J, Geoerger B, et al. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res. 2009;15(14):4561-4571.
16. Zheng PP, Hop WC, Luider TM, Sillevis Smitt PA, Kros JM. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol. 2007;62(1):40-48. (Pubitemid 47235279)
17. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89(1):E1-E7.
18. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005;45(9):1441-1448. (Pubitemid 40615616)
19. Murphy C, Kanaganayagam GS, Jiang B, et al. Vascular dysfunction and reduced circulating endothelial progenitor cells in young healthy UK South Asian men. Arterioscler Thromb Vasc Biol. 2007;27(4):936-942. (Pubitemid 46606728)
20. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N EnglJ Med. 2005;353(10):999-1007. (Pubitemid 41262334)
21. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981-2987. (Pubitemid 40814192)
22. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279-281.
23. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110(3):281-290. (Pubitemid 10204328)
24. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600. (Pubitemid 36204953)
25. Rabbee N, Speed TP. Agenotype calling algorithm for affymetrix SNP arrays. Bioinformatics. 2006;22(1):7-12. (Pubitemid 43057002)
26. Li Y, Abecasis GR. Mach 1.0: Rapid haplotype reconstruction and missing genotype inferenc. Am J Hum Genet. 2006; S79:2290.
27. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847. (Pubitemid 28213628)
28. SAS Institute. SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute; 2000.
29. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62(5):1198-1211. (Pubitemid 28199022)
30. Chen MH, Yang Q. GWAF: an R package for genome-wide association analyses with family data. Bioinformatics. 2010;26(4):580-581.
31. Burton PR, Clayton DG, Cardon LR, et al. Wellcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature. 2007;447(7145):661-678. (Pubitemid 46889737)
32. Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008;112(5):2092-2100.
33. Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endo-thelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151-157.
34. Hong SJ, Choi SC, Kim JS, et al. Low-dose versus moderate-dose atorvastatin after acute myo-cardial infarction:8-month effects on coronary flow reserve and angiogenic cell mobilisation. Heart. 2010;96(10):756-764.
35. Leone AM, Rutella S, Giannico MB, et al. Effect of intensive vs standard statin therapy on endothe-lial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. Int J Cardiol. 2008;130(3):457-462.
36. Schmidt-Lucke C, Fichtlscherer S, Rossig L, Kamper U, Dimmeler S. Improvement of endothe-lial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010;211(1):249-254.
37. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103(24):2885-2890. (Pubitemid 32578123)
38. Hristov M, Fach C, Becker C, et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis. 2007;192(2):413-420. (Pubitemid 46726323)
39. Ludwig A, Jochmann N, Kertesz A, et al. Smoking decreases the level of circulating CD34+ progenitor cells in young healthy women-a pilot study. BMC Womens Health. 2010;10:20.
40. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29(15):1807-1818.
41. Quyyumi AA, Waller EK, Murrow J, et al. CD34 (+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J. 2011;161(1):98-105.
42. Sedoris KC, Thomas SD, Miller DM. Hypoxia induces differential translation of enolase/MBP-1. BMC Cancer. 2010;10:157.
43. Waerner T, Gardellin P, Pfizenmaier K, Weith A, Kraut N. Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis. Cell Growth Differ. 2001;12(4):201-210. (Pubitemid 32678233)
44. Shaw SY, Cheng S, Cupples LA, et al. Genetic and clinical correlates of early-outgrowth colony-forming units. Circ Cardiovasc Genet. 2011;4(3):296-304.
45. Finkel T, Quyyumi AA. Genetic links between circulating cells and cardiovascular risk. Circ Cardiovasc Genet. 2011;4(3):218-220.
46. Timmermans F, Plum J, Yoder MC, Ingram DA, Vanderkerckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med. 2009;13(1):87-102.
47. Sirker AA, Astroulakis ZM, Hill JM. Vascular progenitor cells and translational research: the role of endothelial and smooth muscle progenitor cells in endogenous arterial remodelling in the adult. Clin Sci (Lond). 2009;116(4):283-299.